FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913202470> ?p ?o ?g. }

• W2913202470 endingPage "e13804" @default.
• W2913202470 startingPage "e13804" @default.
• W2913202470 abstract "While checkpoint inhibitors have revolutionized the treatment of melanoma, it is not known whether switching from one monoclonal antibody drug to another one would be justified in the case of a treatment failure. Herein, we report a case illustrating a durable response to pembrolizumab after a failure with nivolumab.A 76-year-old white male noticed an enlarging papular lesion on his neck.Malignant melanoma.The patient underwent surgery in December 2013 and was found to have a B-Rapidly Accelerated Fibrosarcoma (BRAF) V600E mutated melanoma. Treatment with BRAF and MAPK/Erk kinase (MEK) inhibitors along with radiation was initiated. After 1 year, the disease progressed, and the treatment was switched to the cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, ipilimumab. As the tumor did not respond, the treatment was changed to programmed cell death receptor-1 (PD-1) blockers: nivolumab followed by pembrolizumab. Since the initial diagnosis, the tumor response was monitored by computed tomography (CT) scans. Immunohistochemistry (IHC) was also used for the assessment of programmed death ligand 1 PD-L1) expression in the neck, lung, and spleen lesions.The patient had an initial mixed response to nivolumab, but the disease ultimately progressed as evidenced by new metastases to the spleen, thus the treatment was switched to pembrolizumab. After 46 cycles of treatment, all sites of metastases disappeared, including a substantial shrinkage of the splenic metastasis. To gain understanding about the pharmacological differences between nivolumab and pembrolizumab, the PD-1-ligands interactions and conformational dynamics responsible for the PD-1/PD-L1 checkpoint blockade were investigated. The higher affinity of pembrolizumab might likely arise from a unique and large patch of interactions engaging the C'D loop of PD-1, thus forcing an important motion across the PD-1 immunoreceptor.In this case report, we described the tolerance and response of a melanoma patient to a sequence of various agents, including ipilimumab, nivolumab, and pembrolizumab. To the best of our knowledge, this is the first clinical report highlighting differences between PD-1 blockers, as shown by the unexpected and durable response of the tumor to pembrolizumab, after a treatment failure with nivolumab." @default.
• W2913202470 created "2019-02-21" @default.
• W2913202470 creator A5018135274 @default.
• W2913202470 creator A5030012375 @default.
• W2913202470 creator A5038264812 @default.
• W2913202470 creator A5049925756 @default.
• W2913202470 creator A5061512215 @default.
• W2913202470 creator A5063447861 @default.
• W2913202470 creator A5088229078 @default.
• W2913202470 date "2019-01-01" @default.
• W2913202470 modified "2023-10-18" @default.
• W2913202470 title "Nivolumab to pembrolizumab switch induced a durable melanoma response" @default.
• W2913202470 cites W1749548564 @default.
• W2913202470 cites W1752668680 @default.
• W2913202470 cites W1809627231 @default.
• W2913202470 cites W1965370740 @default.
• W2913202470 cites W1990675339 @default.
• W2913202470 cites W2047502920 @default.
• W2913202470 cites W2066671159 @default.
• W2913202470 cites W2082158071 @default.
• W2913202470 cites W2083025888 @default.
• W2913202470 cites W2090031443 @default.
• W2913202470 cites W2100158834 @default.
• W2913202470 cites W2121545342 @default.
• W2913202470 cites W2128035403 @default.
• W2913202470 cites W2132221327 @default.
• W2913202470 cites W2136474966 @default.
• W2913202470 cites W2160766792 @default.
• W2913202470 cites W2163188200 @default.
• W2913202470 cites W2164162782 @default.
• W2913202470 cites W2166262263 @default.
• W2913202470 cites W2168143310 @default.
• W2913202470 cites W2168711434 @default.
• W2913202470 cites W2371704730 @default.
• W2913202470 cites W2469418432 @default.
• W2913202470 cites W2542082502 @default.
• W2913202470 cites W2547310148 @default.
• W2913202470 cites W2560367415 @default.
• W2913202470 cites W2572174216 @default.
• W2913202470 cites W2779503684 @default.
• W2913202470 doi "https://doi.org/10.1097/md.0000000000013804" @default.
• W2913202470 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6336603" @default.
• W2913202470 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30633154" @default.
• W2913202470 hasPublicationYear "2019" @default.
• W2913202470 type Work @default.
• W2913202470 sameAs 2913202470 @default.
• W2913202470 citedByCount "12" @default.
• W2913202470 countsByYear W29132024702019 @default.
• W2913202470 countsByYear W29132024702020 @default.
• W2913202470 countsByYear W29132024702021 @default.
• W2913202470 countsByYear W29132024702022 @default.
• W2913202470 countsByYear W29132024702023 @default.
• W2913202470 crossrefType "journal-article" @default.
• W2913202470 hasAuthorship W2913202470A5018135274 @default.
• W2913202470 hasAuthorship W2913202470A5030012375 @default.
• W2913202470 hasAuthorship W2913202470A5038264812 @default.
• W2913202470 hasAuthorship W2913202470A5049925756 @default.
• W2913202470 hasAuthorship W2913202470A5061512215 @default.
• W2913202470 hasAuthorship W2913202470A5063447861 @default.
• W2913202470 hasAuthorship W2913202470A5088229078 @default.
• W2913202470 hasBestOaLocation W29132024701 @default.
• W2913202470 hasConcept C121608353 @default.
• W2913202470 hasConcept C126322002 @default.
• W2913202470 hasConcept C142724271 @default.
• W2913202470 hasConcept C143998085 @default.
• W2913202470 hasConcept C184235292 @default.
• W2913202470 hasConcept C2776495794 @default.
• W2913202470 hasConcept C2777658100 @default.
• W2913202470 hasConcept C2777701055 @default.
• W2913202470 hasConcept C2779013556 @default.
• W2913202470 hasConcept C2780030458 @default.
• W2913202470 hasConcept C2780057760 @default.
• W2913202470 hasConcept C2780851360 @default.
• W2913202470 hasConcept C2781249067 @default.
• W2913202470 hasConcept C2781433595 @default.
• W2913202470 hasConcept C502942594 @default.
• W2913202470 hasConcept C57074206 @default.
• W2913202470 hasConcept C71924100 @default.
• W2913202470 hasConcept C86803240 @default.
• W2913202470 hasConcept C95444343 @default.
• W2913202470 hasConceptScore W2913202470C121608353 @default.
• W2913202470 hasConceptScore W2913202470C126322002 @default.
• W2913202470 hasConceptScore W2913202470C142724271 @default.
• W2913202470 hasConceptScore W2913202470C143998085 @default.
• W2913202470 hasConceptScore W2913202470C184235292 @default.
• W2913202470 hasConceptScore W2913202470C2776495794 @default.
• W2913202470 hasConceptScore W2913202470C2777658100 @default.
• W2913202470 hasConceptScore W2913202470C2777701055 @default.
• W2913202470 hasConceptScore W2913202470C2779013556 @default.
• W2913202470 hasConceptScore W2913202470C2780030458 @default.
• W2913202470 hasConceptScore W2913202470C2780057760 @default.
• W2913202470 hasConceptScore W2913202470C2780851360 @default.
• W2913202470 hasConceptScore W2913202470C2781249067 @default.
• W2913202470 hasConceptScore W2913202470C2781433595 @default.
• W2913202470 hasConceptScore W2913202470C502942594 @default.
• W2913202470 hasConceptScore W2913202470C57074206 @default.
• W2913202470 hasConceptScore W2913202470C71924100 @default.
• W2913202470 hasConceptScore W2913202470C86803240 @default.

• next